Expression of multidrug‐resistance P‐glycoprotein (MDR1) in human brain tumors

Multidrug resistance (MDR) is associated with the expression of P‐glycoprotein (P‐gp), an ATP‐dependent transporter which expels anti‐cancer drugs from cells. In the present study, MDR1 P‐gp was immunodetected by Western blot analysis in 60 human brain tumors, including meningiomas, schwannomas, low...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of cancer Vol. 93; no. 1; pp. 62 - 66
Main Authors:	Demeule, Michel, Shedid, Daniel, Beaulieu, Édith, Del Maestro, Rolando F., Moghrabi, Albert, Ghosn, Pierre B., Moumdjian, Robert, Berthelet, France, Béliveau, Richard
Format:	Journal Article
Language:	English
Published:	New York John Wiley & Sons, Inc 01-07-2001 Wiley-Liss
Subjects:	Antineoplastic agents Astrocytoma - chemistry ATP Binding Cassette Transporter, Subfamily B, Member 1 - analysis Biological and medical sciences Brain Chemistry Brain Neoplasms - chemistry Brain Neoplasms - secondary brain tumor brain tumors General aspects Glioblastoma - chemistry Humans Lung Neoplasms - pathology MDR1 MDR1 gene Medical sciences Melanoma - pathology meningioma Meningioma - genetics metastasis multidrug resistance Neurilemmoma - genetics Oligodendroglioma - chemistry Pharmacology. Drug treatments P‐glycoprotein Reference Values Antineoplastic agent Human Intracranial Nervous system diseases P Glycoprotein Malignant tumor Gene expression Cerebral disorder Malignant glioma Gene Multiple resistance Central nervous system disease Genetics Negative therapeutic reaction
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Multidrug resistance (MDR) is associated with the expression of P‐glycoprotein (P‐gp), an ATP‐dependent transporter which expels anti‐cancer drugs from cells. In the present study, MDR1 P‐gp was immunodetected by Western blot analysis in 60 human brain tumors, including meningiomas, schwannomas, low‐grade gliomas (astrocytomas, pilocytic astrocytomas) and high‐grade gliomas (anaplastic astrocytomas, glioblastomas and anaplastic oligodendrogliomas). Most samples from primary tumors expressed P‐gp at the same levels as normal brain tissue except for schwannomas, in which levels were reduced by 65%, and meningiomas, in which levels were more than 10‐fold higher in 7 of 10 samples. P‐gp levels were 70% and 95% lower in brain metastases from melanomas and lung adenocarcinomas, respectively, than in normal brain tissue. These results indicate that the majority of primary brain tumors express MDR1 P‐gp and that its high expression levels in meningiomas may be a marker for this type of brain tumor. © 2001 Wiley‐Liss, Inc.
Bibliography:	Fax: +514‐987‐0246 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0020-7136 1097-0215
DOI:	10.1002/ijc.1306